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Introduction
Chromosomal translocations in human leukemia are a source of novel oncogenes termed fusion genes, which encode fusion proteins combining the properties of two distinct proteins. Some genes are involved in multiple oncogenic fusion proteins with distinct partner genes, indicating that the properties of that gene are generally oncogenic if deregulated, or that there are multiple mechanisms by which oncogenic fusion proteins involving the gene can act. The Nucleoporin 98 (NUP98) gene encodes a protein which is normally involved in nuclear transport, but is also recurrent in many different chromosomal translocations in myelodysplastic syndrome (MDS) and acute leukemia [1] . It is among the most promiscuous known fusion gene partners, having been identified in fusion genes with 28 distinct partner genes. The estimated frequency of NUP98 translocations in human leukemia has been recently revised upward, with modern molecular techniques leading to superior detection of these translocations [2, 3] . Further, the NUP98-JARID1A fusion represents a functionally distinct subclass of AML, suggesting that other NUP98 fusions may do the same [2] . Understanding the leukemic activity of the various NUP98 fusions is therefore of increasing importance.
NUP98 fusion partner genes can be broadly broken into two groups: homeobox genes and non-homeobox genes. Homeobox genes are transcription factors defined by the conserved "homeodomain" DNA-binding domain, and this DNA-binding domain is conserved in the fusion proteins with NUP98, of which there are at least ten [1] . This retention of the DNA-binding domain suggests a transcriptional regulatory mechanism for the NUP98-homeobox fusion proteins. Indeed in the case of the NUP98-HOXA9 (NHA9) fusion, this has been directly shown [4] . For the nonhomeobox fusion proteins, of which there are at least eighteen [1] , an overarching mechanism has been slower to emerge. Recent work has suggested that regulation of gene expression by chromatin reading and/or writing via indirect DNA binding is the mechanism for at least some non-homeobox fusion partners [1, 5, 6] , although not all eighteen have the requisite domains for this activity.
We have previously reported the generation of the NUP98-HOXD13 (NHD13) transgenic mouse [7] . Created using the cloned fusion gene from a human MDS under a transgenic vav promoter [8] , the NHD13 mouse develops an MDS by the age of five months (100% penetrance) and an acute leukemia from the age of six months (60%
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A c c e p t e d M a n u s c r i p t 4 penetrance). The only other reported example of a transgenic NUP98 fusion is also a NUP98-homeobox fusion; the NHA9 transgenic mouse is also reported to develop acute myeloid leukemia (AML), albeit at a lower penetrance and later age (22% by 15 months) [9] . No transgenic models of NUP98-non-homeobox fusion genes have been reported, but there are numerous reports of retrovirally-transduced bone marrow models of these genes, which generally result in myeloproliferative neoplasms or AML [5, 6, 10] .
We sought to investigate the relative oncogenic activity of homeobox and nonhomeobox NUP98 fusion genes using similar techniques. To this end, we selected three NUP98 fusion genes to study: NUP98-HOXD13 (NHD13) [11] , NUP98-TOP1 (NT) [12] and NUP98-RAP1GDS1 (NRG) [13] . All of these fusion genes retain the 5' portion of NUP98, including the FG repeats responsible for karyopherin docking during nuclear transport [14] ( Figure 1A ). The 3' portion of HOXD13 that is retained includes the homeodomain, a DNA binding domain. The 3' portion of TOP1 (Topoisomerase 1) that is retained includes the core, linker and catalytic domains used in the protein's normal function of unwinding DNA superstructures [15] . The 3' portion of the NRG fusion retains the entirety (bar the first methionine) of RAP1GDS1 (RAP1 GTP-GDP dissociation stimulator 1), including the armadillo domain.
RAP1GDS1 encodes a protein known as smgGDS, which is involved in guanine nucleotide exchange activity [16] . We created transgenic mouse models expressing NT and NRG from the same vav promoter used in the creation of the NHD13 mouse. We compare phenotype, aberrant gene expression profiles and abnormal self-renewal activity in each of these models to determine the relative oncogenic potency of each of these genes. M a n u s c r i p t
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Material and methods
Generation of transgenic mice
The NUP98-HOXD13 mice have been described previously (Lin et al 2005) . We used the pZVNHD13 vector used in the generation of these mice as the basis for generating the NUP98-TopoisomeraseI (NT) and NUP98-RAP1GDS1 (NRG) mice. Full-length NT and NRG cDNAs were PCR amplified and cloned into the pZVNHD13 vector, replacing the NHD13 sequence in the vector. These resultant vectors (pZVNT and pZVNRG) were sequenced to verify the constructs. The pZVNT and pZVNRG plasmids were digested with PmeI, and the insert containing 5' and 3' vav regulatory elements and the respective fusion gene cDNA were purified by agarose gel electrophoresis and Qiagen gel purification, using the manufacturer's recommendations. The construct was microinjected into zygotes obtained from C57Bl6 mice. Founders were identified using a human NUP98 probe, and offspring were genotyped by PCR amplification of the respective transgene from tail biopsy DNA. Lines were maintained by mating with wild-type C57bl6 mice. All animal experiments were approved by the Animal Care and Use Committee at NCI or the Animal Ethics Committee at Monash University.
Real time PCR
Total DNA was prepared from tail biopsies using standard techniques. Total RNA was prepared from FACS-sorted LK cells by using the Trizol (Invitrogen) reagent according to the manufacturer's instructions. In the case of the hNUP98 PCR, RNA was DNAse-treated using the Turbo DNA-free kit (Ambion Life Technologies). A c c e p t e d M a n u s c r i p t
Results
Generation of NT and NRG transgenic mice
We have previously reported the cloning of the NUP98-TOP1 (NT) [12] and NUP98-RAP1GDS1 (NRG) [13] fusion gene cDNAs from patients with therapy-related myelodysplastic syndrome bearing the t(11;20)(p15;q11) and T-cell acute lymphocytic leukemia bearing the t(4;11)(q21;p15), respectively ( Figure 1A ). We cloned these cDNAs into the identical vav vector used for generation of NHD13 transgenic mice [7] ( Figure 1B) . Following pronuclear injection, we identified four fo under mice for the NT transgene which were able to transmit the transgene through the germline, as determined by PCR genotyping. Three founders were identified for the NRG line which were capable of transmitting the transgene to their offspring. We examined both transgenes to ensure they were expressed, and found them to be expressed exclusively in the hematopoietic compartment (data not shown). To narrow our study, we chose one founder from each of the NT and NRG lines to follow, selecting the one with the highest expression in the marrow.
We examined the relative copy number of each transgene to ensure comparability between the lines. This was achieved by Q-PCR for the shared portion of the human NUP98 gene, using intron-spanning amplicons to ensure that amplification was restricted to the transgenes. To verify this, the endogenous murine Nup98 gene did not amplify from the wild-type mouse. This Q-PCR was normalised using an unrelated A c c e p t e d M a n u s c r i p t 8 NHD13 mice developed hematological phenotype of anemic, lymphopenia and thrombocytopenia by the age of 6 months [7] . In contrast, NT and NRG mice exhibit normal blood counts at six months of age (Figure 2A) , and no anemia, lymphopenia or thrombocytopenia emerge as NT and NRG mice are aged out to 600 days (data not shown).
NHD13 mice have decreased progenitor cells as defined either by FACS staining for the LKS population or functionally by colony assay (CFU-GM) due to increased apoptosis [17] . Consistent with the normal blood counts, numbers of LKS ( Figure 2B) and CFU-GM ( Figure 2C ) in the NT and NRG mice were normal. Examination of mature lineages and progenitors at 12 months of age also revealed no differences between NT or NRG mice and wild type littermates (data not shown).
The thymic CD4/CD8 profiles of NT and NRG mice were normal ( Figure 2D&E ), indicating that differentiation is not impaired in these cells, in contrast to the NHD13 phenotype which shows an increase in CD4/CD8 double negative (DN) thymocytes, consistent with previous results [18] .
Aged cohorts of each strain were monitored for the development of acute leukemia. while NT CFU-GM colonies showed no increased replating ability above wild type ( Figure 4A ). We also conducted standard replating experiments in which 10 5 cells were replated from each plate. In this assay, NHD13 colonies replated indefinitely as previously shown [7] , both NT and NRG colonies replated on the fourth but not the fifth replating, while wild type cells were not able to produce colonies after two replatings ( Figure 4B ). 
M a n u s c r i p t
Discussion NUP98 forms fusion genes with 28 known partner genes in human MDS and leukemia. These partner genes fall into two clear categories; ten are homeobox transcription factors, and the remainder comprise a set of unrelated genes, none of which are known transcription factors [1] . The only noted commonality they share is the presence of at least one coiled-coil domain [21] .
In the present study, we insert two non-homeobox NUP98 fusion genes, NT and NRG, into a transgenic system identical to that previously used to generate the NHD13 mouse model, and find that the two non-homeobox fusions are substantially less potent in this system. While oncogenic potential in transgenic mice can affected by the type of promoter, mouse strain and transgene copy number, these factors are not likely to be resulting in the phenotypic differences seen in this study because all strains were generated using the same vav promoter construct, copy number was similar or higher in the two non-homeobox models, expression at the RNA level was comparable in all three models, and all strains were generated and maintained on a C57BL/6J background.
Phenotypic disease was much less penetrant in both the NT and NRG mice. There was no evidence of a "pre-malignant" phenotype as there is in the NHD13 mice, with peripheral blood counts remaining normal throughout life in the majority of animals.
In late age, 2 of 29 NT mice and 4 of 22 NRG mice developed acute leukemia. This penetrance was greatly reduced in comparison to the 62% of acute leukemia at 365 days of age in the NHD13 cohort. Onset of the disease was also much later in the NT and NRG mice, with no disease apparent prior to 400 days of age. Taken together, we conclude that NT and NRG are less potent oncogenes in this assay than is NHD13.
The cellular effect of most transcription factor fusion proteins is to block differentiation and increase self-renewal [22] . A standard assay for hematopoietic progenitor cell self-renewal is agar colony replating. We use a colony recloning assay as well as the more standard replating assay. Both assays showed that NRG myeloid progenitors have increased self-renewal capacity, but significantly less than those from NHD13 mice. Cells from NT mice showed aberrant self-renewal ability in the standard assay but not in the colony recloning assay, suggesting a mild self-renewal advantage. We conclude that both NT and NRG cells have an increased renewal capability compared to wild type cells, but not to the same extent as do NHD13 cells.
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NUP98-homeobox gene fusions have been widely demonstrated to upregulate
expression of the HOXA cluster [1, 19] , in a manner similar to many MLL fusion genes [23] . Recently, evidence has been presented that NUP98-NSD1 [5] , -PHF23 and -JARID1A [6] cause HOXA cluster overexpression by induction of histone modification changes. Here, we show that two other non-homeobox fusion partners of NUP98 (RAP1GDS and TOP1) have much weaker oncogenic potential than the homeobox fusion partner HOXD13. We propose that this is due to an inability of these two fusions to activate the HOXA gene cluster required for enhanced selfrenewal of progenitors. HOX genes are expressed at high levels in hematopoietic precursors, and expression is gradually extinguished as cells mature (reviewed in [24] ). Increased expression of HOX genes is common in both MDS and AML, and is a driving factor in aberrant self-renewal in these diseases [25] . The measurably increased self-renewal induced by NRG compared to NT is consistent with the increased expression of at least one Hox gene (Hoxb5) in NRG but not NT progenitors.
Our results differ from those of a previous study which used bone marrow transduction to enforce expression of NT [10] . The mice in this study developed AML with 100% penetrance and a median survival of 233.5 days. Possible explanations for the enhanced oncogenic potential in the retroviral system compared to our transgenic system include higher expression of the fusion gene. We have made every effort to ensure that the transgenes are expressed at similar levels, but can not rule out the possibility that different levels of each fusion protein may be present. A more attractive hypothesis to explain the difference between the transgenic and retroviral systems is that cooperative oncogenic hits arise from retroviral insertion effects. This latter hypothesis is supported by the mono-or oligoclonal basis of disease in the original study, and that at leastone such cooperative hit resulting from retroviral insertion was identified [10] . A c c e p t e d M a n u s c r i p t M a n u s c r i p t
